Redo för ett nytt kapitel Priserna på fingeravtryckssensorer till mobilmarknaden har stabiliserats, ...
Q1 i linje med våra estimat Omsättningen i kvartalet uppgick till EUR 12,7m vilket motsvarar en till...
Prostatype Genomics is progressing with the European launch and preparing ahead for the US launch.
Redeye comments on NeoDynamics’ Q1 report and notes several important key activities carried out in ...
VBG Group ökar såväl omsättning som orderingången under Q1 till nya rekordnivåer och värderingen är ...
Q1’22 revenues up 25% (ABGSCe 33%) Strong order intake, despite volatile environment Diversified ord...
Redeye comments on Evaxion’s first quarter report 2022.
Goodbye Kansas Group inleder året starkt och ökar omsättningen och fortsätter att förbättra lönsamhe...
Redeye saw a Q1 report that showed stronger growth and a higher gross margin than expected.
Redeye states that the Q1 report was another step in the right direction in terms of sales and in li...
Relais reported Q1 adjusted EBITA of EUR 6.1m, 36% below Refinitiv consensus estimates and 32% below...
Redeye comments on Mestro’s Q1 2022 report, which was more or less in line with our expectations.
Q1 above expectations, outlook in Russia still poor Prel.
Redeye regards Devyser’s Q1’22 report as strong and was surprised by the high gross margin (83%), wh...
Redeye expected to see some impact from the market turbulence in the Q1 numbers, but the magnitude w...
Q1 revenue was in line with our estimate, with a higher cost base than expected and a somewhat soft ...
NOI +14% vs ABGSCe Property value changes of SEK 110m (+1.
Redeye updates its estimates and valuation for Adverty, following the Q1’22 report.
Redeye är fortsatt positiva till utvecklingen i Irlab efter att ha tagit del av företagets Q1-rappor...
Redeye finds that Gapwaves continues to progress according to plan (both operationally and versus ou...
